Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Articles published by Pfizer Inc.

< Previous 1 2 3 4 5 6 7 8 9
...
11 12 Next >
Pfizer Addresses Proposal for Metsera
From Pfizer Inc.
Via Business Wire
Tickers PFE
XTANDI® Plus Leuprolide Reduced Risk of Death by 40% vs Leuprolide Alone in Men with a Type of Advanced Prostate Cancer
From Pfizer Inc.
Via Business Wire
Tickers PFE
Pfizer’s BRAFTOVI® + MEKTOVI® Shows Sustained Long-Term Survival in Patients with Advanced Lung Cancer
From Pfizer Inc.
Via Business Wire
Tickers PFE
TUKYSA Combination Significantly Improves Progression-Free Survival as First-Line Maintenance in HER2+ Metastatic Breast Cancer in HER2CLIMB-05 Trial
From Pfizer Inc.
Via Business Wire
Tickers PFE
Pfizer to Highlight Advancements in Respiratory Health and Infectious Disease Research at IDWeek 2025
From Pfizer Inc.
Via Business Wire
Tickers PFE
Pfizer Declares Fourth-Quarter 2025 Dividend
From Pfizer Inc.
Via Business Wire
Tickers PFE
Pfizer Reaches Landmark Agreement with U.S. Government to Lower Drug Costs for American Patients
From Pfizer Inc.
Via Business Wire
Tickers PFE
Pfizer Highlights Momentum in Redefining Standards of Care in Cancer at ESMO 2025
From Pfizer Inc.
Via Business Wire
Tickers PFE
Pfizer Invites Public to View and Listen to Webcast of November 4 Conference Call with Analysts
From Pfizer Inc.
Via Business Wire
Tickers PFE
Pfizer to Acquire Metsera and its Next-Generation Obesity Portfolio
From Pfizer Inc.
Via Business Wire
Tickers MTSR PFE
Pfizer and BioNTech Announce Topline Data Demonstrating Robust Immune Response With Their LP.8.1-Adapted COVID-19 Vaccine 2025-2026 Formula
From Pfizer Inc.
Via Business Wire
Tickers BNTX PFE
Pfizer and BioNTech’s COMIRNATY® Receives U.S. FDA Approval for Adults 65 and Older and Individuals Ages 5 through 64 at Increased Risk for Severe COVID-19
From Pfizer Inc.
Via Business Wire
Tickers BNTX PFE
PADCEV™ Plus KEYTRUDA™ Significantly Improves Survival for Certain Patients with Bladder Cancer When Given Before and After Surgery
From Pfizer Inc.
Via Business Wire
Tickers PFE
Pfizer Reports Strong Second-Quarter 2025 Results And Raises 2025 EPS Guidance
From Pfizer Inc.
Via Business Wire
Tickers PFE
Pfizer and BioNTech Receive Positive CHMP Opinion for LP.8.1-adapted COVID-19 Vaccine in the European Union
From Pfizer Inc.
Via Business Wire
Tickers BNTX PFE
Pfizer Completes Licensing Agreement with 3SBio
From Pfizer Inc.
Via Business Wire
Tickers PFE
XTANDI® Plus Leuprolide Significantly Improves Survival Outcomes in Men with Non-Metastatic Hormone-Sensitive Prostate Cancer with High-Risk Biochemical Recurrence
From Pfizer Inc.
Via Business Wire
Tickers PFE
Pfizer Announces Positive Topline Phase 3 Results for HYMPAVZI™ in Hemophilia A or B with Inhibitors
From Pfizer Inc.
Via Business Wire
Tickers PFE
Pfizer Declares Third-Quarter 2025 Dividend
From Pfizer Inc.
Via Business Wire
Tickers PFE
Pfizer Invites Public to View and Listen to Webcast of August 5 Conference Call with Analysts
From Pfizer Inc.
Via Business Wire
Tickers PFE
Pfizer Invites Public to Listen to Webcast of Pfizer Discussion at Healthcare Conference
From Pfizer Inc.
Via Business Wire
Tickers PFE
Pfizer’s BRAFTOVI® Combination Regimen Cuts the Risk of Death in Half for Patients with BRAF V600E-Mutant Metastatic Colorectal Cancer
From Pfizer Inc.
Via Business Wire
Tickers PFE
Pfizer Enters into Exclusive Licensing Agreement with 3SBio
From Pfizer Inc.
Via Business Wire
Tickers PFE
Pfizer Reports Solid First-Quarter 2025 Results And Reaffirms 2025 Guidance
From Pfizer Inc.
Via Business Wire
Tickers PFE
Pfizer’s Sasanlimab Combination Significantly Improves Event-Free Survival in BCG-Naïve, High-Risk Non-Muscle Invasive Bladder Cancer
From Pfizer Inc.
Via Business Wire
Tickers PFE
Pfizer Declares Second-Quarter 2025 Dividend
From Pfizer Inc.
Via Business Wire
Tickers PFE
Pfizer Advances Bold Vision for Future of Cancer Care at the ASCO 2025 Annual Meeting
From Pfizer Inc.
Via Business Wire
Tickers PFE
ACIP Votes to Expand Recommendation for Pfizer’s RSV Vaccine ABRYSVO® to Include Adults Aged 50 to 59 at Increased Risk of Disease
From Pfizer Inc.
Via Business Wire
Tickers PFE
Pfizer Provides Update on Oral GLP-1 Receptor Agonist Danuglipron
From Pfizer Inc.
Via Business Wire
Tickers PFE
Pfizer Invites Shareholders to Attend Virtual 2025 Annual Meeting of Shareholders on April 24
From Pfizer Inc.
Via Business Wire
Tickers PFE
< Previous 1 2 3 4 5 6 7 8 9
...
11 12 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.